Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, pursuant to the Answer of 14 September 2015 to Question 8491, whether interim commissioning arrangements are being considered for nivolumab lung cancer.

NHS England is aware that the National Institute for Health and Care Excellence is reviewing the use of nivolumab in lung cancer, and is likely to report shortly. NHS England has therefore advised that it intends to await the NICE recommendation rather than develop interim arrangements.